Navigation Links
Adamas Pharmaceuticals To Report Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia In Parkinson's Disease
Date:6/10/2013

's disease subjects at 31 study sites in the US (NCT 01397422).  The study's primary efficacy analysis compared ADS-5102 to placebo for reduction in LID over 8 weeks as assessed by the Unified Dyskinesia Rating Scale (UDysRS).  Secondary efficacy outcome measures included changes in a standardized PD diary, including "on time" without troublesome dyskinesia; overall PD clinical status as assessed by the MDS-Unified Parkinson's Disease Rating Scale (MDS-UPDRS); and fatigue measured using the Fatigue Severity Scale.  The EASED trial also included an assessment of dose response for ADS-5102.  The study enrolled male and female subjects aged 30 to 85 years who had Parkinson's disease and were experiencing troublesome LID.  Study participants were randomized to receive a low, medium or high dose of ADS-5102 or placebo once-nightly for eight weeks with a two-week safety follow-up.  Safety measures included adverse events and routine safety laboratory tests that were reviewed during the study by an independent data monitoring committee.  Additional information about the study will be presented in the poster.

About ADS-5102 (Nurelin™)
ADS-5102 is a proprietary, investigational, extended-release formulation of amantadine HCl in development for the treatment of central nervous system (CNS) disorders, including LID in Parkinson's disease.  Designed for once-nightly administration, ADS-5102's unique "chronotherapeutic" profile is characterized by a slow increase in amantadine plasma concentrations, expected to result in high plasma concentrations during the daytime hours when LID can be troublesome, and low plasma concentrations overnight.  The low overnight amantadine plasma concentration may reduce the insomnia, sleep disturbances, and vivid dreams occasionally associated with amantadine.  Due to its altered pharmacokinetic profile, ADS-5102 is being investigated in clinical studies at daily dose strengths gre
'/>"/>

SOURCE Adamas Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Adamas Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA for Arimenda™
2. Access Pharmaceuticals Signs US License Agreement With AMAG Pharmaceuticals For MuGard
3. HemaQuest Pharmaceuticals Completes Patient Enrollment in Phase 2b Clinical Study of HQK-1001 in Patients with Sickle Cell Disease
4. Oramed Pharmaceuticals to Present at IATI-BioMed Conference in Israel
5. DelMar Pharmaceuticals, Inc. Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
6. Valeant Pharmaceuticals Announces Filing Of Preliminary Base Shelf Prospectus
7. Ampio Pharmaceuticals Issues Statement Regarding Misleading Blog
8. Actinium Pharmaceuticals, Inc. Receives $3.5m from Exercise of Warrants
9. Piramal Imaging Highlights New Data for Florbetaben and Other Investigational Radiopharmaceuticals at SNMMI 2013
10. Ampio Pharmaceuticals to List on the NYSE MKT
11. Isis Pharmaceuticals Earns $6 Million Payment from AstraZeneca
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... , Aug. 22, 2014  WaferGen Bio-systems, Inc. ... public offering of units of common stock and warrants ... proceeds of $20 million, prior to deducting underwriting discounts ... The shares and warrants are immediately separable and will ... expected to begin trading on The NASDAQ Stock Market ...
(Date:8/21/2014)... Nektar Therapeutics (NASDAQ: NKTR ... results from its Phase 3 pivotal clinical trial ... factor VIII (rFVIII) treatment for hemophilia A based ... primary endpoint in reducing annualized bleed rates (ABR) ... arm. Top-line results from the prospective, ...
(Date:8/21/2014)... /CNW/ - Eisai Limited is pleased to support the Canadian ... book available in Canada . The comic ... educate children and their parents about epilepsy, the most common ... than 300,000 Canadians. Eisai is guided by a corporate philosophy ... the patient is central – there was a need within ...
Breaking Medicine Technology:WaferGen Bio-Systems Announces Pricing of $20 Million Underwritten Offering and Uplisting to NASDAQ 2WaferGen Bio-Systems Announces Pricing of $20 Million Underwritten Offering and Uplisting to NASDAQ 3WaferGen Bio-Systems Announces Pricing of $20 Million Underwritten Offering and Uplisting to NASDAQ 4Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 2Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 3Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 4Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 5Eisai Pleased to Support Canadian Epilepsy Alliance Comic Book that Teaches Children About Epilepsy 2
... , June 14 Upsher-Smith Laboratories, Inc. today ... for USL255 (extended-release topiramate), an internally developed program for the ... technology.  USL255 is designed to provide convenient once-daily dosing and ... topiramate options. , , ...
... /PRNewswire/ -- MedShape Solutions, Inc. was recently ... for their MORPHIX™ Suture Anchor at the recent Medical ... of jurors awarded the MORPHIX™ Anchor the Gold Award ... proprietary shape memory polymer, PEEK Altera™.  Previous winners of ...
Cached Medicine Technology:Upsher-Smith Laboratories Announces Initiation of Phase III Clinical Trial of USL255 (Extended-Release Topiramate) for Adjunctive Treatment of Partial-Onset Epilepsy 2Upsher-Smith Laboratories Announces Initiation of Phase III Clinical Trial of USL255 (Extended-Release Topiramate) for Adjunctive Treatment of Partial-Onset Epilepsy 3MedShape Solutions, Inc. Receives Industry Honors and Awards 2
(Date:8/23/2014)... 23, 2014 Professional kitchen employees, prospective ... aid in preparing for Food Safety Certification exams thanks ... by Dynamic Path. , Dynamic Path announced the release ... more than 200 review questions for culinary industry students ... to cover requirements of the ServSafe® Food Safety Certification, ...
(Date:8/23/2014)... TX (PRWEB) August 23, 2014 Youth ... of Texas. It’s no different in Houston, TX. Substance ... are falling victim to drug and alcohol dependency in ... are looking to beat substance abuse, but don’t know ... juvenile treatment facility can be a challenge because most ...
(Date:8/22/2014)... Search Engine Optimization is needed to bring a ... and get more audience and sales. Top 10 ... hosting suppliers and announced that HostGator.com ( http://secure.hostgator.com/~affiliat/cgi-bin/affiliates/clickthru.cgi?id=seohosts ... hosting suppliers for webmasters from the USA, UK, ... Linux hosting (including VPS and cloud hosting). , ...
(Date:8/22/2014)... 23, 2014 Recently, Skmen.com, an experienced ... of 2014 bohemian dresses in its online store. Moreover, ... prices, up to 28% off. All the international clients ... August 31, 2014. , The company’s professional online ... to show worldwide customers more the latest information about ...
(Date:8/22/2014)... NV (PRWEB) August 22, 2014 ... that is written by marketing experts for marketers to ... links has caught the attention of Shane Michaels, prompting ... with Internet marketing in any way knows that content ... in the industry,” reports Michaels. “But even though content ...
Breaking Medicine News(10 mins):Health News:Food Handler Safety Certification Made Easy with Dynamic Path 2Health News:New Houston Hotline Assisting Juveniles in Locating Dependable Rehabilitation Help 2Health News:Top10BestSEOHosting.com Announces Best Cheap Hosting Suppliers Of This Summer 2Health News:Cheap Bohemian Dresses Unveiled by Experienced Supplier Skmen.com 2Health News:My Writers: Review Exposes Online Source for Quality Marketing Content 2
... today (Oct. 31) announced that it is partnering with ... Medical School to administer a transformative $7.2 million project ... in Liberia, an African nation with which IU has ... the Center for Excellence in Health and Life Sciences ...
... to tackle hospital-acquired infections, such as C. difficile ... infections following specific surgical procedures. That is the key ... of the urology journal BJUI . UK ... a standard surgical procedure to diagnose prostate cancer developed ...
... Certain factors unique to professional sports can increase the risk ... staff, a new report suggests. Norovirus is the most ... and causes 21 million cases of illness in the United ... 31 online edition of the journal Clinical Infectious Diseases ...
... a 2010 outbreak involving several NBA teams, the ... a professional sports association. Published in Clinical ... ), the study highlights unique circumstances for spreading ... on and off the court. Norovirus ...
... 2011)In a technical tour de force, scientists at Fox ... of 178 candidate drugs capable of blocking the activity ... critical for cancer and other diseases. Additionally, a free ... to the research community. This unique library represents an ...
... , SUNDAY, Oct. 30 (HealthDay News) --,A physically active ... a new study. Glaucoma, a leading cause of blindness, ... damages the optic nerve. In this study, researchers looked ... 5,650 men and women aged 48 to 90 in Britain. ...
Cached Medicine News:Health News:$7.2 million project will address a national shortage of health-care workers in Liberia 2Health News:$7.2 million project will address a national shortage of health-care workers in Liberia 3Health News:$7.2 million project will address a national shortage of health-care workers in Liberia 4Health News:$7.2 million project will address a national shortage of health-care workers in Liberia 5Health News:Drugs used to tackle hospital-acquired infections can increase post-op complications 2Health News:Stomach Bug Easily Passed Among Pro Sports Teams: Report 2Health News:NBA players not immune to serious illness from norovirus 2Health News:First-of-its-kind study creates new tool for targeted cancer drug development 2Health News:First-of-its-kind study creates new tool for targeted cancer drug development 3Health News:Glaucoma Experts Eye Benefits of Exercise 2
... Provides a more occlusive wrap than ... where wound transudate must be contained. Predictable ... be inert, nonantigenic, and nonpyrogenic. ,VICRYL (polyglactin ... synthetic absorbable copolymer of glycolide and lactide, ...
Used for implantation to reinforce soft tissue. Supplied sterile in peel-open packages. Intended for one-time use....
... mesh onlays are pre-cut and pre-shaped to ... are more frequently done. These pre-shaped onlays ... ProLite Ultra and are designed for use ... in both small and large sizes, they ...
... such as laparoscopic inguinal hernia repair ... a surgical biomaterial that enables rapid ... provides the answer to the most ... Made from strong, soft, inert and ...
Medicine Products: